Download PDFPDF

Which B-cell subset should we target in lupus?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:

    Dear Editor,

    We thank Aramugakani et al. for their critical reading of our Editorial (1) accompanying Cheng et al. paper on the role of long-lived plasma cells (PC) in driving murine lupus nephritis (LN) (2). First, we obviously share - and explicitely mentioned - the safety issues related to long-lived PC depletion, in particular a possible high infection rate. Second, our purpose was not to question the effe...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Reply to: Which B-cell subset should we target in lupus?
    • Gururaj Arumugakani, Clinical Research Fellow
    • Other Contributors:
      • Dr.Edward Vital, Dr.Yuzaiful Yusof, Prof.Dennis McGonagle, Prof.Paul Emery

    Dear Editor,

    We read with interest the editorial by Ferraccioli and Houssiau proposing the specific targeting of long lived plasma cells (PCs) in human lupus nephritis (LN) [1]. The authors present a cogent summary of experiments showing that long-lived PCs alone are sufficient to induce murine LN, and that targeting of PCs in these models is successful. However, we believe that clinical experience with the treatme...

    Show More
    Conflict of Interest:
    None declared.